The Pharmacokinetics/Pharmacodynamics Core (Core D) will provide analytic resources to each of the Projects in this application to measure concentrations of drugs and relevant biomarkers within various sample types. This will primarily be accomplished using a mass spectrometric approach, with which the principal investigator has significant expertise. Methods to detect drug and drug metabolites have already been developed for both the lead (P2176) and backup (P2114) compounds and successfully utilized to assess the pharmacokinetics of these drugs when applied to the airways. Similarly, methods to measure relevant biomarkers have been developed and yield biologically plausible results in preliminary experiments. Furthermore, the Core has the capability of adding new biomarkers as the need arises.
The Pharmacokinetics/Pharmacodynamics Core (Core D) will provide the Projects in this application with the ability to measure concentrations and physiological effects of novel mucolytic drugs designed to treatment airways disease cystic fibrosis or asthma. These analyses will be available to all Projects within the proposal, as well as to the wider scientific community.
Showing the most recent 10 out of 76 publications